相关临床试验
24
12 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2013
进行中（未招募）
2
8.3%
已完成
3
12.5%
尚未招募
10
41.7%
招募中
9
37.5%
暂无批准数据
- RedHill Biopharma has initiated patient recruitment for a Phase 2 study evaluating opaganib plus darolutamide in men with metastatic castrate-resistant prostate cancer, sponsored by ANZUP and supported by Bayer. - The innovative 60-patient trial uses a precision medicine approach with the PCPro lipid biomarker test to identify patients with poor prognosis who may benefit most from the combination therapy. - The study aims to overcome resistance to standard androgen receptor pathway inhibition treatment, with opaganib targeting three sphingolipid-metabolizing enzymes to enhance darolutamide efficacy. - Prostate cancer represents a significant global burden with 1.5 million new cases annually and a $12 billion market, making this precision medicine approach particularly valuable for advanced disease management.
- RedHill Biopharma initiates an 80-patient Phase 2 study testing opaganib in combination with Bayer's darolutamide for metastatic castrate-resistant prostate cancer, with financial backing from Bayer and Ramsay Hospital Research Foundation. - The study will utilize a novel PCPro biomarker test to identify patients with poor prognosis who may benefit from the combination therapy, with the primary endpoint being 12-month radiographic progression-free survival. - Prostate cancer affects approximately 1.5 million new patients annually worldwide, with the study targeting a significant unmet need in the $12 billion market for patients who develop resistance to standard treatments.
